Literature DB >> 15042605

Imaging of bioluminescent LNCaP-luc-M6 tumors: a new animal model for the study of metastatic human prostate cancer.

Caroline D Scatena1, Mischa A Hepner, Yoko A Oei, Joan M Dusich, Shang-Fan Yu, Tony Purchio, Pamela R Contag, Darlene E Jenkins.   

Abstract

BACKGROUND: Animal experiments examining hormone-sensitive metastatic prostate cancer using the human LNCaP cell line have been limited to endpoint analyses. To permit longitudinal studies, we generated a luciferase-expressing cell line and used bioluminescent imaging (BLI) to non-invasively monitor the in vivo growth of primary LNCaP tumors and metastasis.
METHODS: LNCaP.FGC cells were transfected to constitutively express firefly luciferase. LNCaP-luc-M6 cells were tested for bioluminescent signal intensity and hormone responsiveness in vitro. The cells were implanted in subcutaneous and orthotopic sites in SCID-bg mice and imaged over time.
RESULTS: The LNCaP-luc-M6 cells formed subcutaneous and orthotopic tumors in SCID-bg mice, and nearly all tumor-bearing animals developed pulmonary metastases. Early detection and temporal growth of primary tumors and metastatic lesions was successfully monitored by BLI.
CONCLUSIONS: The LNCaP-luc-M6 cell line is a bioluminescent, hormone-sensitive prostate cancer cell line applicable for BLI studies to non-invasively monitor subcutaneous and orthotopic prostate tumor growth and metastasis in vivo. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15042605     DOI: 10.1002/pros.20003

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  19 in total

1.  Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3K)/AKT pathways.

Authors:  Jun-ichi Hanai; Nathaniel Doro; Atsuo T Sasaki; Susumu Kobayashi; Lewis C Cantley; Pankaj Seth; Vikas P Sukhatme
Journal:  J Cell Physiol       Date:  2012-04       Impact factor: 6.384

2.  In vitro validation of bioluminescent monitoring of disease progression and therapeutic response in leukaemia model animals.

Authors:  Yusuke Inoue; Arinobu Tojo; Rieko Sekine; Yasushi Soda; Seiichiro Kobayashi; Akiko Nomura; Kiyoko Izawa; Toshio Kitamura; Toshiyuki Okubo; Kuni Ohtomo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-05       Impact factor: 9.236

3.  Assessing tumor growth and distribution in a model of prostate cancer metastasis using bioluminescence imaging.

Authors:  Justin M Drake; Curtis L Gabriel; Michael D Henry
Journal:  Clin Exp Metastasis       Date:  2006-05-16       Impact factor: 5.150

4.  Anti-metastatic effects of liposomal gemcitabine in a human orthotopic LNCaP prostate cancer xenograft model.

Authors:  Peter Jantscheff; Vittorio Ziroli; Norbert Esser; Ralph Graeser; Jessica Kluth; Alena Sukolinskaya; Lenka A Taylor; Clemens Unger; Ulrich Massing
Journal:  Clin Exp Metastasis       Date:  2009-09-26       Impact factor: 5.150

5.  Non-invasive detection of a small number of bioluminescent cancer cells in vivo.

Authors:  Jae-Beom Kim; Konnie Urban; Edward Cochran; Steve Lee; Angel Ang; Bradley Rice; Adam Bata; Kenneth Campbell; Richard Coffee; Alex Gorodinsky; Zhan Lu; He Zhou; Takashi Kei Kishimoto; Peter Lassota
Journal:  PLoS One       Date:  2010-02-23       Impact factor: 3.240

6.  Efficacy of c-Met inhibitor for advanced prostate cancer.

Authors:  William H Tu; Chunfang Zhu; Curtis Clark; James G Christensen; Zijie Sun
Journal:  BMC Cancer       Date:  2010-10-14       Impact factor: 4.430

7.  TRAIL-coated leukocytes that prevent the bloodborne metastasis of prostate cancer.

Authors:  Elizabeth C Wayne; Siddarth Chandrasekaran; Michael J Mitchell; Maxine F Chan; Rachel E Lee; Chris B Schaffer; Michael R King
Journal:  J Control Release       Date:  2015-12-28       Impact factor: 9.776

8.  Targeting of the Akt-nuclear factor-kappa B signaling network by [1-(4-chloro-3-nitrobenzenesulfonyl)-1H-indol-3-yl]-methanol (OSU-A9), a novel indole-3-carbinol derivative, in a mouse model of hepatocellular carcinoma.

Authors:  Hany A Omar; Aaron M Sargeant; Jing-Ru Weng; Dasheng Wang; Samuel K Kulp; Tushar Patel; Ching-Shih Chen
Journal:  Mol Pharmacol       Date:  2009-08-25       Impact factor: 4.436

9.  A Model-Based Personalized Cancer Screening Strategy for Detecting Early-Stage Tumors Using Blood-Borne Biomarkers.

Authors:  Sharon Seiko Hori; Amelie M Lutz; Ramasamy Paulmurugan; Sanjiv Sam Gambhir
Journal:  Cancer Res       Date:  2017-03-10       Impact factor: 12.701

10.  Bioluminescent imaging of intracranial vestibular schwannoma xenografts in NOD/SCID mice.

Authors:  Brian A Neff; Stephen G Voss; Cory Allen; Mark A Schroeder; Colin L W Driscoll; Michael J Link; Evanthia Galanis; Jann N Sarkaria
Journal:  Otol Neurotol       Date:  2009-01       Impact factor: 2.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.